Abstract

Sevelamer Suspension in Children with End-Stage Renal Disease

Author(s): McElhiney Linda F

Issue: Jan/Feb 2007 - Pediatric Patients

Page(s): 20-24

Download in electronic PDF format for $75
  • Sevelamer Suspension in Children with End-Stage Renal Disease Page 1
  • Sevelamer Suspension in Children with End-Stage Renal Disease Page 2
  • Sevelamer Suspension in Children with End-Stage Renal Disease Page 3
  • Sevelamer Suspension in Children with End-Stage Renal Disease Page 4
  • Sevelamer Suspension in Children with End-Stage Renal Disease Page 5

Abstract

Control of hyperphosphatemia is a major clinical challenge in children with end-stage renal disease. The best treatment option is a calcium-based phosphate binder, but there is evidence that this treatment protocol causes long-term complications, including vascular calcifications. Sevelamer hydrochloride has been shown to be effective in reducing serum phosphorus levels and the calcium-phosphorus ion product in children on maintenance dialysis and may be key in preventing soft-tissue and vascular calcifications in such patients. Until the U.S. Food and Drug Administration approves the use of sevelamer hydrochloride in children undergoing dialysis, and a liquid dosage form becomes available, compounding pharmacists will need to prepare this unique compound for these patients.

Related Keywords

  • CHILDREN, INFANTS, CHRONIC RENAL FAILURE, KIDNEY FAILURE, END-STAGE RENAL DISEASE, ESRD, HYPERPHOSPHATEMIA, FIXED OIL, RENAGEL, DIALYSIS, PHOSPHORUS, PHOSPHATE BINDERS, SEVELAMER HYDROCHLORIDE, ORAL SUSPENSION, LIQUID PREPARATIONS, DOSAGE FORMS, FORMULATI

Related Categories

  • FORMULATIONS
  • NUTRITION AND NUTRICEUTICALS
  • PEDIATRICS
  • STABILITIES, COMPATIBILITIES
  • UROLOGY/URINARY TRACT

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Jan/Feb 2007
Pg. 20-24
Sevelamer Suspension in Children with End-Stage Renal Disease
Author(s): McElhiney Linda F
Sep/Oct 2012
Pg. 364-368
Compounded Oral Ketamine for Severe Depression, Anxiety, and Pain in a Hospice Patient with End-stage Chronic Obstructive Pulmonary Disease, Cardiopulmonary Failure, and Severe Renal Insufficiency: A Case Report
Author(s): McNulty Jack P, Hahn Kristian
Jul/Aug 2003
Pg. 288-291
Basics of Compounding for Raynaud's Disease
Author(s): Glasnapp Andrew
May/Jun 2003
Pg. 188-191
Treating Canine Hepatic Disease
Author(s): Davidson Gigi S
Sep/Oct 2010
Pg. 382-394
Conservative Management of Chronic Kidney Disease in Cats: Recommendations for Veterinarians and Compounding Pharmacists
Author(s): Meadows Richard L, Muller George
May/Jun 2016
Pg. 247-249
Extended Stability of Morphine and Sildenafil for Oral Use in Infants and Young Children
Author(s): Nahata Milap C
Sep/Oct 2022
Pg. 436-439
Effects of Calcium Polystyrene Sulfonate Formulation Change from Dry Syrup to Oral Solution in Patients with Chronic Kidney Disease
Author(s): Kobayashi Shunsuke, Ogawara Yuka, Imamura Yoshihiko, Kitaoka Akira, Yasu Takeo
Mar/Apr 2011
Pg. 124-128
Proton Pump Inhibitor Homogenous Suspensions: A Compounding Solution to Pediatric Gastroesophageal Reflux Disease
Author(s): Corsini Lindsay, Williams LaVonn A
Jan/Feb 2012
Pg. 34-41
Compounded Pimobendan for Canine Chronic Degenerative Mitral Valve Disease and Pulmonary Hypertension
Author(s): Helms Scott R, Fox Samantha, Mixon William, Vail Jane
May/Jun 2016
Pg. 257-261
Development of Extemporaneously Compounded Aripiprazole Oral Suspensions for Use in Children
Author(s): Pramann Lance A, Davidow Lawrence W, van Haandel Leon, Funk Ryan S
Mar/Apr 2015
Pg. 143
Aminohippurate Sodium 200-mg/mL Injection
Author(s): Allen Loyd V Jr
Jul/Aug 2022
Pg. 293-296
Compounding for Juvenile Idiopathic Arthritis and Other Pediatric Rheumatic Diseases
Author(s): Harrington Amy, Williams LaVonn
Jan/Feb 2014
Pg. 61
Bumetanide 0.25-mg/mL Injection
Author(s): Allen Loyd V Jr
Mar/Apr 2010
Pg. 108-111
Coenzyme Q10 Supplementation in the Treatment of Heart Disease
Author(s): Bramwell Bethany L
Jul/Aug 1997
Pg. 242-243
Case Reports: Osteomyelitis in a Young Draft Horse; Quarter Horse Gelding with Chronic Obstructive Pulmonary Disease
Author(s): Patterson Donna, Ford Peter R, Gallon Marlene D
Nov/Dec 2018
Pg. 516-526
Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4
Author(s): Polonini Hudson, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira
Jan/Feb 2019
Pg. 14-21
The History, Symptoms, Causes, Risk Factors, Types, Diagnosis, Treatments, and Prevention of Gout, Part 2
Author(s): Williams LaVonn A
Sep/Oct 2006
Pg. 390
Oral Rehydration Salts (World Health Organization/United Nations Children's Fund)
Author(s): Allen Loyd V Jr
Sep/Oct 2009
Pg. 367-371
Congestive Heart Failure and Other Medical Facts About Ferrets; Scout's Story: A Case Report on Treating Congestive Heart Failure in a Ferret
Author(s): Williams LaVonn A, Riley Kari
Jul/Aug 2007
Pg. 338-346
Statistical Analysis of Barrier Isolator/Glovebox Glove Failure
Author(s): Park Young H, Pines E, Ofouku M, Cournoyer ME